The utilization of lenvatinib with pembrolizumab for the treatment of recurrent endometrial cancer.

• DOI: 10.1200/jco.2023.41.16_suppl.e17627
• Publication Date: 2023-06-04T15:55:31Z
• Authors: Mali Barbi; Chung-Shien Lee; Husneara Rahman; Kit Cheng; Lee Jean; Veena S. John
• Keywords: Lenvatinib

e17627 Background: The landscape for the treatment of microsatellite-stable-recurrent endometrial cancer has changed with published results KEYNOTE-775, demonstrating an overall response rate 37.2% Pembrolizumab and Lenvatinib 20 mg. However, recent retrospective studies have suggested that a lower dose may be safer equally efficacious. We aimed to retrospectively review our institutional data compare efficacy toxicity at low (≤10 mg) vs. high (>10 dose. Methods: Retrospective patients recurrent who received ≥ 3 cycles Lenvatinib. A Univariate analysis was used estimate 1-year progression-free survival (PFS) (OS), Multivariate Cox PH regression model hazard ratio (HR) 95% confidence interval (CI) p<0.05. Results: 77 were included in this analysis, median age BMI 70 years 28.5 kg/m2, respectively (Table 1). Most tumors PDL-1<1% (67.2%) microsatellite stable (95%). 4 had MSI-H. started (66%, 10 mg), 34% higher (n=26, 14 mg). most common mg (41%, n=32) 13% (n=10). In group, 71% ECOG 0-1 77% dose, more likely > 2 lines (45% 22%). time interruption 41 51 days respectively. PFS OS not statically different showed significantly HR group (2.5 [CI 1.12-5.56], p=0.025). Conclusions: TheFDA-recommended is perceived difficult tolerate are often on study, we observed longer than group. Though failed detect significant differences PFS/OS, when adjusted age, progression or death Possible explanations observations older frailer. Our findings call question practice starting Further warranted delineate required both efficacious safe. [Table: see text]